Der Klinikarzt 2018; 47(01/02): 12-20
DOI: 10.1055/s-0044-101505
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Klinische Erkenntnisse zu moderner i.v.-Eisentherapie

Welche Neubewertungen sind notwendig?
Andera Salama-Müller
1   Klinik für Innere Medizin, Gastroenterologie und Onkologie, Oberschwabenklinik Ravensburg
,
Susanne Reuther
2   Vifor Pharma Deutschland GmbH, München
,
Patrick Meybohm
3   Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Frankfurt
,
Günther J. Wiedemann
1   Klinik für Innere Medizin, Gastroenterologie und Onkologie, Oberschwabenklinik Ravensburg
,
Matthias Leschke
4   Klinik für Kardiologie, Angiologie und Pneumologie, Esslingen
› Author Affiliations
Further Information

Publication History

Publication Date:
14 February 2018 (online)

Zusammenfassung

Die Erfahrungen zur modernen i. v.-Eisentherapie aus den letzten 10 Jahren zeigen deutlich, dass im Rahmen der Diagnostik und Therapie des Eisenmangels und der Eisenmangel-Anämie insbesondere bei Bestehen von chronischen Grunderkrankungen, eine Neubewertung verschiedener Parameter sowie Hypothesen notwendig ist. Des Weiteren zeigen zahlreiche klinische Ergebnisse, dass Eisenmangel von der Eisenmangelanämie als eigene Entität deutlich abzugrenzen ist, da durch den alleinigen Eisenmangel ein erheblich schlechterer klinischer Verlauf sowie eine erhöhte Rehospitalisierungs-, Morbiditäts- und Mortalitätsrate zu beobachten ist.

 
  • Literatur

  • 1 Hastka J, Heimpel H, Metzgeroth G. et al. Eisenmangel und Eisenmangelanämie. Onkopedia 2011; 1-24
  • 2 Kassebaum NJ. The Global Burden of Anemia. Hematology/Oncology Clinics of North America 2016; 30: 247-308
  • 3 Haehling von S, Ottenjann H, Anker SD. Iron deficiency: Recognition and treatment. Internist (Berl) 2017; 58: 627-638
  • 4 Cappellini MD, Comin Colet J, de Francisco A. et al. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am J Hematol 2017; 92: 1068-1078
  • 5 Ponikowski P, van Veldhuisen DJ, Comin Colet J. et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†. Eur Heart J Oxford University Press 2015; 36: 657-668
  • 6 Anker SD, Comin Colet J, Filippatos G. et al. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. N Engl J Med 2009; 361: 2436-2448
  • 7 Lewis GD, Malhotra R, Hernandez AF. et al. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. JAMA American Medical Association 2017; 317: 1958-1966
  • 8 Stein J, Bager P, Befrits R. et al. Anaemia management in patients with inflammatory bowel disease: routine practice across nine European countries. Eur J Gastroenterol Hepatol 2013; 25: 1456-1463
  • 9 Evstatiev R, Marteau P, Iqbal T. et al. FERGIcor, a Randomized Controlled Trial on Ferric Carboxymaltose for Iron Deficiency Anemia in Inflammatory Bowel Disease. YGAST 2011; 141: 846-853.e2
  • 10 Gotloib L, Silverberg D, Fudin R. et al. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol 2006; 19: 161-167
  • 11 Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?. Oncologist 2004; 9 (Suppl. 05) 31-40
  • 12 Ludwig H, Müldür E, Endler G. et al. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol 2013; 24: 1886-1892
  • 13 Ponikowski P, Voors AA, Anker SD. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016; 37: 2129-2200
  • 14 Klip IT, Comin Colet J, Voors AA. et al. Iron deficiency in chronic heart failure: An international pooled analysis. Am Heart J 2013; 165: 575-582.e3
  • 15 Peyrin-Biroulet L, Williet N, Cacoub P. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J Clin Nutr 2015; 102: 1585-1594
  • 16 Kempf T, Bavendiek U, Bauersachs J. Neue medikamentöse Therapieansätze bei chronischer Herzinsuffizienz. Internist 2017; 58: 990-999
  • 17 Leichtle SW, Mouawad NJ, Lampman R. et al. Does preoperative anemia adversely affect colon and rectal surgery outcomes?. J Am Coll Surg 2011; 212: 187-194
  • 18 Goodnough LT, Maniatis A, Earnshaw P. et al. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. Br J Anaesth 2011; 106: 13-22
  • 19 Meybohm P, Schmitz-Rixen T, Steinbicker A. et al. The patient blood management concept: Joint recommendation of the German Society of Anaesthesiology and Intensive Care Medicine and the German Society of Surgery. Chirurg 2017; 88: 867-870
  • 20 Meybohm P, Müller MM, Zacharowski K. Preoperative Preparation: Patient Blood Management – What is Optimal?. Anasthesiol Intensivmed Notfallmed Schmerzther 2017; 52: 326-340
  • 21 Musallam KM, Tamim HM, Richards T. et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. The Lancet 2011; 378: 1396-1407
  • 22 Heymann von C, Kaufner L, Sander M. et al. Does the severity of preoperative anemia or blood transfusion have a stronger impact on long-term survival after cardiac surgery?. J Thorac Cardiovasc Surg 2016; 152: 1412-1420
  • 23 Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs 2009; 69: 739-756
  • 24 Froessler B, Palm P, Weber I. et al. The Important Role for Intravenous Iron in Perioperative Patient Blood Management in Major Abdominal Surgery: A Randomized Controlled Trial. Ann Surg 2016; 264: 41-46
  • 25 Jankowska EA, Tkaczyszyn M, Suchocki T. et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail 2016; 18: 786-795
  • 26 Jankowska EA, Rozentryt P, Witkowska A. et al. Iron Deficiency Predicts Impaired Exercise Capacity in Patients With Systolic Chronic Heart Failure. J Card Fail 2011; 17: 899-906
  • 27 Ezekowitz JA. Anemia Is Common in Heart Failure and Is Associated With Poor Outcomes: Insights From a Cohort of 12 065 Patients With New-Onset Heart Failure. Circulation 2003; 107: 223-225
  • 28 Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol 2010; 7: 599-610
  • 29 Ponikowski P, Metra M, Teerlink JR. et al. Design of the RELAXin in acute heart failure study. Am Heart J 2012; 163: 149-155.e.1
  • 30 Haehling von S, Ottenjann H, Anker SD. Eisenmangel bei chronischer Herzinsuffizienz. Klinikarzt 2017; 46: 484-490
  • 31 Vischer AS, Pfister O. Eisenmangel bei Patienten mit chronischer Herzinsuffizienz. info@herz+gefaessch 2017; 1-4
  • 32 Meybohm P, Richards T, Isbister J. et al. Patient Blood Management Bundles to Facilitate Implementation. Transfus Med Rev 2017; 31: 62-71
  • 33 Lipp HP. Eisen i. v. und die Aut-idem-Problematik. Deutsche Apotheker Zeitung 2016; 156: 1-6
  • 34 Toblli ET, Cao G, Angerosa M. The Induction of Oxidative/Nitrosative Stress, Inflammation, and Apoptosis by a Ferric Carboxymaltose Copy Compared to Iron Sucrose in a Non-Clinical Model. JCDR 2015; 1-5
  • 35 Eisenblätter T. Generic drug, biosimilar, NBCD similar – A new category of generic drugs: On the consequences for the liability of doctor, pharmacist and pharmaceutical entrepreneur. Pharmazeutische Industrie 2012; 74: 266-276
  • 36 Breymann C, Milman N, Mezzacasa A. et al; FER-ASAP investigators Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP). J Perinat Med 2017; 45: 443-453
  • 37 Neiser S, Koskenkorva T, Schwarz K. et al. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA). Int J Mol Sci 2015; 16: 17514-17534 2016; 17: 1185–1110
  • 38 Koskenkorva-Frank TS, Weiss G, Koppenol WH. et al. The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species – Insights into the potential of various iron therapies to induce oxidative and nitrosative stress. Free Radic Biol.Med 2013; 65: 1174-1194
  • 39 Ponikowski P, Filippatos G, Colet JC. et al. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. Eur J Heart Fail 2015; 17: 329-339
  • 40 Anker SD, Kirwan BA, van Veldhuisen DJ. et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail 2017; 127: e6
  • 41 Neumann T, Biermann J, Erbel R. et al. Heart failure: the commonest reason for hospital admission in Germany: medical and economic perspectives. Dtsch Arztebl Int 2009; 106: 269-275
  • 42 Christ M, Störk S, Dörr M. et al. Heart failure epidemiology 2000–2013: insights from the German Federal Health Monitoring System. Eur J Heart Fail 2016; 18: 1009-1018
  • 43 Jankowska EA, Rozentryt P, Witkowska A. et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010; 31: 1872-1880 Eur Heart J 2011; 32: 1054–1054
  • 44 Kaldara-Papatheodorou EE, Terrovitis JV, Nanas JN. Anemia in heart failure: should we supplement iron in patients with chronic heart failure?. Pol Arch Med Wewn 2010; 120: 354-360
  • 45 Doehner W, Blankenberg S, Erdmann E. et al. Iron Deficiency in Chronic Heart Failure: Diagnostic Algorithm and Present-Day Therapeutic Options. Dtsch med Wochenschr 2017; 142: 752-757
  • 46 van Veldhuisen DJ, Ponikowski P, van der Meer P. et al. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. Circulation 2017; 136: 1374-1383
  • 47 Ponikowski P, van Veldhuisen DJ, Comin Colet J. et al. Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. ESC Heart Fail 2014; 1: 52-58
  • 48 Anker SD, Colet JC, Filippatos G. et al. Rationale and design of Ferinject® Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail 2009; 11: 1084-1091
  • 49 Stein J, Dignass AU. Management of iron deficiency anemia in inflammatory bowel disease – a practical approach. Ann Gastroenterol 2013; 26: 104-113
  • 50 Gasche C, Lomer MCE, Cavill I. et al. Iron, anaemia, and inflammatory bowel diseases. Gut 2004; 53: 1190-1197
  • 51 Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med 2004; 116 (Suppl 7A) 44S-49S
  • 52 Cosnes J, Gower Rousseau C, Seksik P. et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011; 140: 1785-1794
  • 53 Goldberg ND. Iron deficiency anemia in patients with inflammatory bowel disease. Clin Exp Gastroenterol 2013; 6: 61-70
  • 54 Reinisch W, Staun M, Bhandari S. et al. State of the iron: how to diagnose and efficiently treat iron deficiency anemia in inflammatory bowel disease. J Crohns Colitis 2013; 7: 429-440
  • 55 Stein J, Aksan A, Farrag K. et al. Management of inflammatory bowel disease- related anaemia and iron deficiency with specific reference to the role of intravenous iron in current practice. Expert Opin Pharmacother 2017; 18: 1721-1737
  • 56 Dignass AU, Gasche C, Bettenworth D. et al. European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases. J Crohns Colitis 2015; 9: 211-222
  • 57 Okam MM, Koch TA, Tran MH. Iron Supplementation, Response in Iron-Deficiency Anemia: Analysis of Five Trials. Am J Med 2017; 130: 991.e1-991.e8
  • 58 Lee T, Clavel T, Smirnov K. et al. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut 2017; 66: 863-871
  • 59 Koduru P, Abraham BP. The role of ferric carboxymaltose in the treatment of iron deficiency anemia in patients with gastrointestinal disease. Therapeutic Advances in Gastroenterology. SAGE PublicationsSage UK; London, England: 2015. 9 76-85
  • 60 Preiß JC, Bokemeyer B, Buhr H. et al. Updated German clinical practice guidelines on "Diagnosis and treatment of Crohn's disease" 2014. Z Gastroenterol 2014; 52: 1431-1484
  • 61 Kulier A, Gombotz H. Perioperative Anämie. Anaesthesist 2001; 50: 73-86
  • 62 Zacharowski K. Patient Blood Management. Forum Sanitas – Das informative Medizinmagazin 2017; 6-8
  • 63 Zacharowski K. Präoperative Vorbereitung. Anasthesiol Intensivmed Notfallmed Schmerzther 2017; 52: 324-325
  • 64 Delaney M, Wendel S, Bercovitz RS. et al. Transfusion reactions: prevention, diagnosis, and treatment. Lancet 2016; 388: 2825-2836
  • 65 Aapro M, Haehling von S, Jelkmann W. et al. Anämie- und Blutmanagement. Deutsch Ärztebl 2017; 29-32
  • 66 Bernard AC, Davenport DL, Chang PK. et al. Intraoperative Transfusion of 1 U to 2 U Packed Red Blood Cells Is Associated with Increased 30-Day Mortality, Surgical-Site Infection, Pneumonia, and Sepsis in General Surgery Patients. J Am Coll Surg 2009; 208: 931-937 937 e1–2; discussion 938–939
  • 67 Baron DM, Hochrieser H, Posch M. et al. Preoperative anaemia is associated with poor clinical outcome in non-cardiac surgery patients. Br J Anaesth 2014; 113: 416-423
  • 68 Fowler AJ, Ahmad T, Phull MK. et al. Meta-analysis of the association between preoperative anaemia and mortality after surgery. Br J Surg 2015; 102: 1314-1324
  • 69 Glance LG, Dick AW, Mukamel DB. et al. Association between intraoperative blood transfusion and mortality and morbidity in patients undergoing noncardiac surgery. Anesthesiology 2011; 114: 283-292
  • 70 Ferraris VA, Hochstetler M, Martin JT. et al. Blood transfusion and adverse surgical outcomes: The good and the bad. Surgery 2015; 158: 608-617
  • 71 Kotzé A, Carter LA, Scally AJ. Effect of a patient blood management programme on preoperative anaemia, transfusion rate, and outcome after primary hip or knee arthroplasty: a quality improvement cycle. Br J Anaesth 2012; 108: 943-952
  • 72 Khalafallah AA, Yan C, Al-Badri R. et al. Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial. Lancet Haematol 2016; 3: e415-e425
  • 73 Meybohm P, Herrmann E, Steinbicker AU. et al. Patient Blood Management is Associated With a Substantial Reduction of Red Blood Cell Utilization and Safe for Patient’s Outcome: A Prospective, Multicenter Cohort Study With a Noninferiority Design. Ann Surg 2016; 264: 203-211
  • 74 Schlenke P, Spahn DR. Patient Blood Management: It Is Time to Streamline Targeted Therapy Options. Transfus Med Hemother 2015; 42: 72-73
  • 75 Muñoz M, Acheson AG, Auerbach M. et al. International consensus statement on the peri-operative management of anaemia and iron deficiency. Anaesthesia 2017; 72: 233-247